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Induced sputum is increasingly used to detect and monitor airway inflammation in respiratory diseases. However,
the processing of sputum has been rather laborious for clinical practice.
The aim of this study was to improve the practicality of induced-sputum studies by simplifying sample
processing. Eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), neutrophil lipocalin (HNL) and
myeloperoxidase (MPO) were used as biochemical markers of airway inflammation and the results of the study
method were compared with a previously validated (reference) method.
Induced sputum was obtained from 42 healthy controls, 10 subjects with acute respiratory infection, eight
patients with chronic obstructive pulmonary disease (COPD) and 17 asthmatics. The sputum sample was divided
into two parts and treated either: (i) by the reference method (released markers), where sputum was homogenized
with dithiotreitol and centrifuged to yield cell-free supernatant and a cell pellet, or (ii) by the study method (total
markers), where the cells were lysed after homogenization so that cell-associated markers were released and
solubilized. For comparison, the four biochemical markers were measured in sputum supernatant and in sputum
lysate. The differential cell count was performed from the cell pellet in the reference method. Repeatability was
assessed in a group of 16 subjects. The effect of reagents and the recovery of assays were also evaluated.
Released and total markers correlated well (ECP rs=0?80, P50?0001; EPO rs=0?49, P50?0001; HNL rs=0?87,
P50?0001; MPO rs=0?71, P50?0001). Incubation with dithiotreitol and lysis reagent had no negative influence on
marker assays. The within-subject variability of total ECP, MPO and HNL in both methods was small in two
measurements taken 1 week apart.
The study method, measuring total inflammatory markers, gave comparable results to the reference method,
measuring released markers. In the study method the sputum processing was simplified, which may improve its
applicability.
Key words: asthma; chronic obstructive pulmonary disease; eosinophil cationic protein; eosinophil peroxidase;
induced sputum; infection; human neutrophil lipocalin; myeloperoxidase.
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Characteristic features of asthma and chronic obstructive
pulmonary disease (COPD) are airflow limitation and
bronchial inflammation. In these conditions increased
numbers of activated inflammatory cells are found in
bronchial biopsy specimens, in bronchoalveolar lavage
(BAL) fluid, in sputum and in severe cases in peripheral
blood (1–4). In asthma, eosinophils are considered to be theReceived 7 April 2000 and accepted in revised form 26 September
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Correspondence should be addressed to: Tuula Metso, Skin and
Allergy Hospital, Division of Allergy, Helsinki University Central
Hospital, Meilahdentie 2, FIN-00250 Helsinki, Finland. Fax:
+358-9-47186500; E-mail: tuula.metso@sci.fi
0954-6111/01/010048+08 $35?00/0effectory cells, whereas the role of neutrophils is more
controversial. In patients with COPD, respiratory infec-
tions or asthma exacerbations increase the numbers of
neutrophils that are present in the airways. Both eosino-
phils and neutrophils contain in their intra-cellular granules
various mediators that are released on activation.
A practical method is needed to evaluate airway
inflammation and to identify predominant granulocytes in
different clinical situations. Bronchoalveolar lavage and
bronchial biopsies have been widely used to obtain samples
and specimens to study cellular and biochemically soluble
granulocyte markers, but the invasiveness of bronchoscopic
methods limit their usage. Inducing sputum is a less
invasive and a safe method to investigate airway inflamma-
tion (4). It has been shown to be clinically valid and reliable
(5–7) and it has given results comparable to those obtained# 2000 HARCOURT PUBLISHERS LTD
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ples are more concentrated in cells and biochemical
constituents than BAL samples obtained by fibre-optic
bronchoscopy (9). Sputum is derived from the diseased
organ and reflects local inflammation better than measure-
ments from blood (12).
Sputum processing for biochemical and cellular analysis
has varied (4,7,13–18), and information obtained from
different studies cannot be accurately compared. Hargreave
et al. have validated the processing method for cellular and
biochemical measurements (7,19). The method was mod-
ified for sputum induction and processing to improve its
clinical applicability by the authors.
The study was designed with two objectives: (i) to
compare cellular profiles and biochemical markers for
eosinophils (ECP, eosinophil cationic protein; EPO, eosi-
nophil peroxidase) and neutrophils (MPO, myeloperoxi-
dase; HNL, human neutrophil lipocalin) by two sputum-
processing methods, and (ii) to validate the sputum
processing of the study method. The patients included
had acute respiratory infection, COPD or asthma. A group
of healthy subjects was also included
Methods
SUBJECTS AND CLINICAL METHODS
The study population consisted of 42 healthy subjects, 10
patients with acute respiratory infections, eight with
COPD, and 17 with asthma (Table 1). All subjects gave
informed consent for the study, which was approved by the
hospital ethics committee.
Healthy subjects with no history of asthma, other
respiratory symptoms or respiratory infection within 4
weeks were recruited from the hospital staff and their
relatives. Their peak expiratory flow (PEF) values (Spira
Peak Flow1, Ha¨meenlinna, Finland) were within the
normal range (20). Ten healthy subjects with acute
respiratory tract infection for less than 1 week were also
recruited. The microbial aetiology of the infection was not
assessed, but symptoms were characteristic of acute viral
infection of the respiratory tract. These patients had normalTABLE 1. Characteristics of the 77 study subjects
Characteristics Healthy individals Res
n=42




PEF (% of predicted){ 103.6 (87–120) 1
FEV1 (% of predicted)
{ n.d.
Data are expressed as mean and range or *number and percentag
{defined as at least one positive allergy skin prick test (wheal PEF values. Eight patients with a previous diagnosis of
COPD (21) and a smoking history of 20 to 80 pack years
were included. They were clinically stable and their mean
forced expiratory volume in 1 sec (FEV1) was 43% of
predicted volume with less than 10% bronchodilatation
response to inhaled salbutamol (Buventol Easyhaler1, 200
microg/dose, Orion Pharma, Espoo, Finland). All asthma
patients had reversible airway obstruction with either at
least 15% bronchodilatation response in FEV1 to 200 mg
inhaled salbutamol or at least 20% diurnal variation in
PEF values, for at least 3 days during a 2 week follow-up
period. All asthmatics showed increased bronchial respon-
siveness to inhaled histamine with means PD20FEV1 of
0?35mg (22). None of the COPD and asthma patients had
received anti-inflammatory medication (inhaled corticoster-
oid, sodium cromoglycate or sodium nedocromile) or had
had an exacerbation or respiratory infection within 4
weeks.
SPUTUM INDUCTION
Sputum was induced by inhalation of 5ml of 3% NaCl
solution using a small ultrasonic nebulizer (Omron U1,
Omron, Germany). According to the manufacturer, the
output is about 0?25ml min71 and the mean mass media of
nebulized saline solution ranges from 1 to 7mm. Peak
expiratory flow values were measured before and after
induction to ensure the procedure was safe. No pre-
medication was used. Subjects were asked to cough during
and after inhalation and to expectorate into empty
containers.
SPUTUM PROCESSING
Sputum samples were transferred to a Petri dish and the
more viscous parts were collected using forceps. Sputum
plugs (selected from saliva) were first mixed with forceps
and then divided into two parts to compare two different
methods for sputum processing. Sample parts were
processed either: (i) by the reference method described by
Pizzichini et al. (7) to collect cells and cell-free supernatant
(released markers), or (ii) by the study method, where thepiratory infection COPD Asthma
n=10 n=8 n=17
38.9 (19–56) 68.2 (58–76) 42.2 (18–72)
6/4 5/3 10/7
1 (10) 8 (100) 6 (35)
1 (10) 0 (0) 9 (53)
01.8 (93–116) 51.3 (28–64) 83.7 (53–109)
n.d. 42.7 (27–66) 85.0 (69–101)
e of patients; COPD: chronic obstructive pulmonary disease;
3mm); {reference values from Viljanen (34); n.d. not done.
50 T. METSO ET AL.sample was treated first with dithiotreitol (DTT) as well as
with a cetyl-N,N,N-trimethylammonium bromide (CTAB)
detergent in order to lyse the cells and then to collect
supernatant markers (total markers).
In the reference method (released markers), a four-fold
volume of 6.5mmol 171 dithiotreitol (Sputolysin1, Calbio-
Chem, LaJolla, CA, U.S.A.) diluted 10-fold in distilled
water, was added to the sputum sample and the mixture
was incubated for 15min in a roller mixer at room
temperature. An equal volume of phosphate-buffered saline
(PBS) was added, and incubation was continued for
another 5min. The mixture was filtered using 53mm
nylon-mesh filter (Nybolt PA-53/35, Seidengaze, Ger-
many). Sputum cells were separated by centrifugation at
800 g for 10min and the sputum supernatant was collected
for measurements of fluid-phase markers. Cells obtained
after centrifugation were resuspended in 1 ml of PBS and
the total cell number was determined using a haemocyt-
ometer. Viability was measured by the Trypan Blue
exclusion test. The cell suspension was cytocentrifuged
(Cytospin 3, Shandon, Astmoor, U.K.) on to the Vecta-
bond-treated (Vectabond1 Reagent, Vector Laboratories,
Inc., CA, U.S.A.) microscope slides at 450 rpm for 4min.
Slides were air-dried for at least 30min. One slide was used
for differential staining with the May-Gru¨nwald-Giemsa
(MGG) method. Two slides were fixed using Carnoy’s
fixative and stained using toluidine blue for detection of
metachromatic cells (basophils, mast cells). A minimum of
400 non-squamous cells was counted in MGG-stained
slides and 1500 in toluidine blue-stained slides with a
standard light microscope. Results were expressed as
percentages of the total non-squamous count.
In the study method (total markers), a four-fold volume
of 6?5mmol171 DTT was added to the sputum sample, as
in the reference method, and the mixture was incubated for
15min in a roller mixer at room temperature. Differently
from the reference method, a five-fold volume of CTAB
reagent (0?5% CTAB, 0?4% HSA 100 mM PBS, pH 7?2)
was added after 15min and the mixture was incubated for
1 h in a roller mixer. By this measure, cells were lysed and
granulocyte markers inside and outside the cells were
released and solubilized (23). Sputum supernatant was
separated from cell debris by centrifugation at 800 g for
10min. The resulting clear suspension was aspirated,




Concentrations of ECP (g l71) in thawed supernatants
were determined using an immunoassay kit (CAP System
FEIA ECP, Pharmacia & Upjohn Diagnostics, Uppsala,
Sweden), and levels of MPO (g l71) using a double-
antibody RIA kit (MPO RIA, Pharmacia & Upjohn
Diagnostics, Uppsala, Sweden). Concentrations of EPO
(g l71) and HNL (g l71) were determined using proto-
type kits (CAP System FEIA, Pharmacia & Upjohn
Diagnostis, Uppsala, Sweden), as previously described(24). Results were adjusted for dilutions and all measure-
ments were performed in duplicate.
CONTROL EXPERIMENTS
To evaluate the within-subject variability of induced
sputum, a group of 16 subjects gave induced-sputum
samples twice in a 1-week interval. The group consisted
of 12 healthy subjects (mean age 44 years, 11 females) with
normal PEF values, and four asthma patients (mean age 42
years, three females) with the mean FEV1 75.5% predicted.
Sputum samples were analysed with both the reference
method and the study method. To examine the effect of
DTT and CTAB on marker assays of total ECP, a standard
curve with DTT and CTAB was made and compared with
the curve with physiological saline. Recovery of ECP was
examined by adding stock solutions of ECP standards to
three different sputum samples pre-incubated with DTT
and CTAB. Control experiments for EPO, MPO and HNL
were performed analogously.
DATA ANALYSIS
Data are expressed as means or medians and ranges, as
some values were below the lowest standard point. All
results were included in data analysis. Results with
immeasurable values were processed by giving the numer-
ical value of the lowest standard point. Significances of
differences between the four study groups were first
analyzed using Kruskal-Wallis one-way analysis by ranks.
When significant differences between groups were observed,
inter-group comparisons were assessed by a non-parametric
method using the Wilcoxon–Mann U-test. For correlation
between variables the Spearman rank-order test was used.
A two-tailed P-value of 0?05 or less was considered
significant. Repeatability of marker measurements was
expressed as intra-class correlation coecient (Ri) (25)
using log-transformed values.
Results
All subjects tolerated the sputum-induction procedure well.
The median percentage of squamous epithelial cell con-
tamination was 5.4% (range 0–72%) from all subjects
(n=77). In all subjects the cell viability was over 80%.
Patients with asthma and COPD showed no significant
differences in the mean proportions of sputum eosinophils,
but both groups had more eosinophils than patients with
respiratory infection or healthy persons (Table 2).
CORRELATION OF RELEASED
BIOCHEMICAL MARKERS TO TOTAL
MARKERS
Concentrations of both released and total ECP and EPO
were highest among patients with COPD. Patients with
respiratory infection and COPD had significantly higher
TABLE 2. Cytospin cell counts in induced sputum obtained by the previously validated (reference) method (7)
Characteristics Healthy individuals Respiratory infection COPD Asthma
n=42 n=10 n=8 n=17
Total cells (106) 1.91 (0?03–12.9) 2.82 (0?16–5.86) 1.16 (0?34–3.96) 0?78 (0?01–3.60)
Eosinophils (%)* 0?31 (0?0–4.9) 0?80 (0?0–2.3) 3.57 (0?0–7.9) 17.84 (0?0–89.5)
Neutrophils (%)* 37.9 (3.0–87.5) 82.9 (68.4–92.4) 73.4 (46.3–90?5) 45.2 (3.1–81.9)
Macrophages (%)* 53.5 (7.7–96.3) 15.0 (5.5–28.9) 19.8 (5.1–51.2) 36.7 (6.6–90?7)
Lymphocytes (%) 0?51 (0?0–3.7) 0?28 (0?0–1.1) 0?33 (0?0–2.3) 0?63 (0?0–1.9)
Bronchial epithelial cells (%) 7.75 (0?0–67.0) 1.05 (0?0–7.6) 2.89 (0?0–16.3) 2.4 (0?0–19.9)
Squamous epithelial cells (%) 14.1 (0?0–67.0) 8.05 (0?0–35.8) 20?9 (0?3–72.0) 13.7 (0?0–60?0)
Metachromatic cells (%)** 0?0 (0?0–0?0) 0?08 (0?00–0?73) 0?0 (0?0–0?0) 0?08 (0–0?53)
Data are expressed as median and range. *P50?001, **P50?02 for differences between the four groups, Kruskal-Wallis;
COPD: chronic obstructive pulmonary disease.
TABLE 3. Concentrations of inflammatory markers in induced sputum obtained by the reference method (measuring released
markers) and the study method (measuring total markers)
Inflammation markers Healthy individuals Respiratory infection COPD Asthma
mg l71 n=42 n=10 n=8 n=17
Total ECP* 572 (68–2706) 4937 (397–21160) 5840 (681–15400) 2485 (386–69940)
Released ECP* 140 (19–985) 1329 (67–14202) 2104 (88–3726) 748 (60–5647)
Total EPO* 45.0 (525.0–6830) 47.7 (37–162) 3550 (380–7435) 632 (45–41654)
Released EPO* 5.2 (54.5–121 35.6 (54.4–1436) 166.5 (9–517) 83.5 (5.1–2927)
Total HNL** 6199 (1146–19324) 31789 (1956–138077) 18774 (1645–44898) 4059 (2446–20330)
Released HNL*** 5549 (1005–27855) 26249 (1854–95580) 14304 (2260–34182) 6215 (2448–22643)
Total MPO* 178 (580–1524) 3402 (146–57600) 7125 (395–58000) 192 (580–21800)
Released MPO* 572 (572–1555) 599 (–72–4027) 1490 (144–3429) 572 (572–572)
Total ECP/MPO** 2.2 (0?3–11.2) 0?9 (0?2–6.1) 0?7 (0?2–11.5) 7.6 (0?2–219.6)
Total ECP/HNL* 0?09 (0?02–0?58) 0?15 (0?05–0?31) 0?34 (0?29–0?45) 0?48 (0?05–6.46)
Data are expressed as median and range. ECP: Eosinophil cationic protein; EPO: eosinophil peroxidase; HNL: neutrophil
lipocalin; MPO: myeloperoxidase. *P50?001, **P50?001, ***P50?01 for differences between the four groups, Kruskal-
Wallis.
GRANULOCYTE MARKERS IN INDUCED SPUTUM 51concentrations of both released and total MPO and HNL
(Table 3).
Correlation between released and total marker concen-
trations [Fig. 1(a–d)] was excellent for ECP (rs=0?80,
P50?0001) and for HNL (rs=0?87, P50?0001), good for
MPO (rs=0?71, P50?0001) and moderate for EPO
(rs=0?49, P50?0001), when all study groups were included
in the evaluation. Not surprisingly, correlation varied
between study groups and markers [see legends for Fig.
1(a–d)]. For example, released EPO concentrations corre-
lated significantly with total EPO concentrations in the
asthma group, but not so well in patients with respiratory
infection or COPD or in healthy persons. On the other
hand, strong correlation for released and total ECP and for
released and total HNL results was observed in all groups.
The ratio of eosinophil and neutrophil markers, total
ECP/MPO, was able to differentiate healthy persons from
all patient groups. The ratio of total ECP/HNL differ-
entiated healthy persons from patients with asthma orCOPD. Both indices demonstrated significant differences
between groups (total ECP/MPO: P=0?0002; total ECP/
HNL: P50?0001; Kruskal-Wallis).
CORRELATION OF RELEASED AND TOTAL
BIOCHEMICAL MARKERS TO SPUTUM
CELLS
Released and total ECP and EPO correlated significantly
with eosinophil percentages (rs=0?52 for released ECP,
P5?0001; rs=0?62 for total ECP, P50?0001; rs=0?67 for
released EPO, P50?0001; rs=0?69 for total EPO,
P50?0001) when all study groups were included. Similarly,
released and total HNL and MPO correlated to neutrophil
percentages (rs=0?52 for released HNL, P50?0001;
rs=0?65 for total HNL, P50?0001; rs50?56 for released
MPO, P50?0001; rs=0?56 for total MPO, P50?0001). The
power of correlation somewhat varied between the study
FIG. 1. Correlation between released and total (a) eosinophil cationic protein (ECP), (b) eosinophilperoxidase (EPO), (c)
neutrophillipocolin (HNL) and (d) myeloperoxidase (MPO). All values are expressed as mg l71. Due to the number of
undetectable values some correlations for healthy persons, patients with respiratory infection and patients with asthma are
not given. Correlation was for ECP rs=0?80, P50?0001, for EPO rs=0?49, P50?0001, for HNL rs=0?87, P50?0001 and
for MPO rs=0?71, P50?0001, when all study groups were included. Results for some patients are missing because of the
limited volume of sputum supernatants. ~: healthy; &: respiratory infection; *: chronic obstructive pulmonary disease
(COPD); &: asthma.
52 T. METSO ET AL.group and marker. For instance, in asthmatics, but not in
patients with COPD and in healthy individuals, significant
correlation between eosinophil percentage and total ECP
and EPO concentrations was found.
CONTROL EXPERIMENTS AND
REPEATABILITY
The addition of DTT and CTAB to the reference protein
did not change the shape of standard curves (data not
shown). Recoveries for total markers were acceptable
(between 80% and 120%). For ECP it was 102?1% (mean),
for EPO 96?6%, for HNL 100?5% and for MPO 99?7%,
indicating that corresponding proteins were not bound to
pre-treated sputum sample influencing the analysis.
The repeatability (Ri) was good for released ECP (0?85),
total ECP (0?78), released MPO (0?97), total MPO (0?90),
released HNL (0?91), total HNL(0?61), and poorer for
released EPO (0?52) and total EPO (0?22).
Discussion
The previously validated sputum processing method (7) was
modified in order to improve its clinical applicability. In
this modified method, sputum specimens for measurementof various biochemical markers can be frozen and stored
after collection, so that specimens can be taken in one place
(e.g. in a healthcare centre) and processed and analysed in
another (e.g. in a central laboratory). The study method for
sputum processing gives results comparable to those
obtained by the reference method (7). By measuring one
eosinophil-activation marker, ECP, and one neutrophil
marker, MPO, with a commercially available kit, airway
inflammation can be studied with reasonable accuracy.
Incubation of the reference protein with DTT and CTAB
showed no negative influence on the marker assays.
Recovery of four markers (ECP, EPO, MPO and HNL)
ranged from 96?6% to 102?1%.
Sputum processing for obtaining cytospin slides
and differential cell counts is laborious and can be
used in larger laboratories. The prerequisite for reliable
cytospin slides is processing the sputum immediately
rather than later. This is only possible in large laboratories.
The advantage of the study method (which measures
total markers) over the reference method (which measures
released markers) is its relative simplicity allowing
small laboratories, that do not have cytocentrifuge to use
it. The amount of inflammatory cells can be studied in a
semi-quantitative manner from smears made prior to
freezing using eosin-methylene-blue staining (26). Sputum
induction and collection of sputum plugs is the same in
both methods.
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methods of sputum processing. The first methodological
choice, affecting both cellular and biochemical marker
results, in whether to use the entire sample, including
variable amounts of saliva (13), or only a selected part
(plugs) of the sample (7). Concentrations for biochemical
markers have been assayed from (i) sputum supernatants
(7,13), from (ii) the entire expectorates including cells and
supernatant (16,17), and from (iii) cell pellets (27). The first
alternative measures the extracellular, secreted form of a
marker, which may reflect the degree of cell activation.
However, it may be dicult to assess whether markers have
pre-existed in the airways or were released because of
hypertonic saline inhalation or sample treatment, as has
been hypothesized for albumin and fibrinogen (28). The
second alternative measures both intra- and extracellular
marker concentrations and thus reflects both the activity
and the size of the source-cell population in the airways.
The third alternative is suggested to correlate with absolute
number of sputum cells.
The authors’ approach was to measure the total marker
concentrations (intra- and extracellular) in sputum selected
from saliva. It was found that analysing the whole sample
content of plugs is simple and gives results comparable to
markers released in the supernatant. All sputum-processing
methods with differential cell counting published so far are
relatively laborious. The relative simplicity of our method
may be an advantage if the method is recommended for
wider use.
Sputum plugs were first treated with DTT and then
subjected to CTAB. The DTT treatment is necessary since
liquidification of sputum plugs is desired prior to CTAB
treatment. The detergent was added in order to lyse the cells
and to liberate biochemical markers possibly engulfed by
other cells. CTAB was chosen as a detergent since sticky
proteins such as ECP can be eciently recovered from the
cell pellet by 1-h CTAB treatment, as shown by Carlson et
al. (23). In-vitro studies have shown that at least apoptotic
eosinophils and neutrophils are recognized and phagocy-
tozed by macrophages (29,30) and they could therefore be
an additional source of granule proteins when using this
extraction procedure. The highly cationic proteins EPO and
ECP have a tendency to stick to cell surfaces and to form
insoluble aggregates. Tendency to bind to surfaces of test
tubes has also been noticed during the purification of EPO
(31). Control experiments showed that neither DTT nor
CTAB had any negative effects on marker assays.
Correlation between released and total marker concen-
trations was excellent, but varied depending both on the
study group and the cellular source of a marker in question.
In asthma and COPD, the two eosinophil-derived markers,
released and total ECP, as well as released and total EPO,
correlated significantly. Strong correlation between released
and total MPO, as well as released and total HNL, was
observed in patients with infection and with COPD.
An index that evaluates the amount of eosinophils in
relation to neutrophils may be useful in differential
diagnostics. A ratio of total ECP to total MPO differ-
entiated healthy subjects from the patients with asthma,
COPD or respiratory infection. In addition, it distinguishedasthmatics from COPD patients and from patients with
respiratory infection. A ratio of total ECP to total HNL
revealed a less clear difference between the study groups.
The findings, with regard to the cellular and biochemical
composition of induced sputum in patients with asthma
and COPD, and in healthy controls, are in line with reports
by others (12,13,18). In the present study, sputum
eosinophils correlated significantly with total ECP and
total EPO in patients with asthma. Concentrations of HNL
and MPO were significantly correlated with neutrophil
numbers in COPD patients and in subjects with respiratory
infection. This suggests that eosinophilic inflammation
associated with asthma and neutrophilic inflammation
associated with airway infection and with COPD can be
detected by sampling the airways using the two different
techniques presented here.
In a study by Lacoste (2), neither the numbers of
neutrophils nor the concentrations of MPO were increased
in BAL fluids or in mucosal biopsies in most asthmatic
patients. In contrast, patients with COPD showed increased
numbers of neutrophils and concentrations of MPO in
BAL fluids (2). In the present study, released-MPO levels
were undetectable in all asthma patients and in 66% of
control subjects, but never in COPD patients or subjects
with respiratory infection. The strong correlation observed
between MPO and ECP in patients with acute respiratory
infection suggests that factors that prime neutrophils
during respiratory infection may also have an effect on
eosinophils. Venge et al. have recently reported an active
uptake of ECP by neutrophils (32). This might partly
explain the observed correlation, since ECP is suggested to
co-localize with MPO in the secondary granules of
neutrophils. The absence of increased levels of EPO at the
same time could be explained by the unresponsiveness of
the mechanisms leading to EPO release, as recently
suggested (33).
Repeatability of differential cell counts and measure-
ments of soluble inflammatory markers have been good in
samples obtained on different days from clinically stable
patients (5,7). A slightly better repeatability was reported in
moderate-to-severe asthmatics compared with those with
mild asthma (5). A good repeatability for all marker
measurements was found except for EPO, irrespective of
the technique of sputum processing used.
In conclusion, a simplified method for measuring
granulocyte markers has been described. Total marker
assays were able to differentiate patients with respiratory
disorders from healthy individuals. Total marker assays
also gave comparable results with previously established
released-marker assays. The results suggest that the induced
sputum method with total marker assays may be used in
clinical practice.
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